While most shows and films of late have become rife with overstimulation, violence, and immeasurable plot twists, sometimes ...

“The Dreamin’ Kind” is Langhorne Slim’s ninth studio album and finds the Pennsylvania-born, Nashville-based artist strapping on an electric guitar and embracing his longtime love of larger-than-life ...

Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the top-selling drug by 2030. Lilly raised its quarterly dividend 15% to $1.73 per share. The ...

Its lineup and pipeline put it well ahead of even its closest competitor. The drugmaker should continue riding this wave for the foreseeable future. Furthermore, Novo Nordisk is anticipating ...

Eli Lilly (LLY) submitted an FDA application for orforglipron. The once-daily oral pill maintained weight loss after patients switched from injections. Lilly’s Zepbound achieved 20.2% average weight ...

The Edmonds-Woodway High School Jazz Ensemble I has been to be selected for 2026 Starbucks Hot Java Cool Jazz concert, EWHS Jazz Band Director Jake Bergevin announced Thursday. The concert […] ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Eli Lilly’s ...

Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from obesity-related complications. The company has a diversified portfolio across ...

In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today. The big story around Eli Lilly is the success of its GLP-1 drugs Mounjaro (for diabetes) and Zepbound (for weight ...

Eli Lilly & Co. (NYSE: LLY)'s dominance in obesity therapeutics looks increasingly difficult to challenge, and Bank of America believes the market is still underestimating just how much growth lies ...

Eli Lilly is positioned for a secular growth trajectory, leveraging its duopoly in diabetes and obesity therapies while investing heavily in pipeline diversification. LLY faces intensifying ...

Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook is strong, and the stock is a buy, even at current levels. 10 stocks we like ...